Ask the Experts: Progression and Resistance
laurabbook@gmail.com2021-01-21T14:27:05-08:00*January 2021* The first of three webinars on Progression and Resistance in EGFR+ lung cancer. This first webinar is on Histological
21 January 2021
21 January 2021
Enriching Responses With Targeted Therapy in NSCLC
laurabbook@gmail.com2021-01-21T14:17:08-08:00*December 2020* EGFR, ALK, and ROS1 abnormalities are no longer the only oncogenic drivers worthy of discussion in non–small cell lung cancer (NSCLC),
21 January 2021
Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy
laurabbook@gmail.com2021-01-21T14:11:00-08:00*December 2020* Robust data on the outcome of MET-aberrant non-small cell lung cancer (NSCLC) with non-targeted therapies is limited, especially in
21 January 2021
Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine
laurabbook@gmail.com2021-01-21T13:51:07-08:00*December 2020* Identification of key oncogenic drivers and the development of targeted therapies with clinical activity in patients harboring actionable
21 January 2021
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
laurabbook@gmail.com2021-01-21T13:43:12-08:00*November 2020* Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, efficiently penetrates the blood-brain barrier. This study explored whether treatment with
21 January 2021
Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC
laurabbook@gmail.com2021-01-21T13:33:16-08:00*December 2020* Because no standard approaches exist for patients with EGFR-mutated non–small cell lung cancer (NSCLC) who progress on standard frontline
21 January 2021
Frontline Regimens Explored for EGFR-Mutated NSCLC
laurabbook@gmail.com2021-01-21T13:25:21-08:00*December 2020* John Heymach, MD, PhD Chair, Department of Thoracic/Head and Neck Medical Oncology The University of Texas MD Anderson
6 January 2021
New Clinical Trial: Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
laurabbook@gmail.com2021-01-06T14:40:10-08:00*November 2020* This new clinical trial is for those people whose EGFR lung cancer has transformed to small cell lung
6 January 2021
Neratinib Shows Early Activity in EGFR Exon 18–Mutated, Metastatic NSCLC
laurabbook@gmail.com2021-01-06T14:30:12-08:00*November 2020* Neratinib (Nerlynx) showcased early activity when used in patients with metastatic non–small cell lung cancer (NSCLC) who harbor EGFR exon
6 January 2021
Inhibitors of MET, RET, and TRK Now Enjoy Standard of Care Status in Lung Cancer
laurabbook@gmail.com2021-01-06T14:24:51-08:00*November 2020* In the treatment of lung tumors, alterations in MET as well as gene fusions in RET and NTRK